at a glance
Post kala azar dermal Leishmaniasis
01 April 2018 to 30 June 2023
European Vaccine Initiative
8 Mio Euro
Clinical development of a therapeutic vaccine for prevention of post-kala azar dermal leishmaniasis
The PREV_PKDL project aims at advancing the clinical development of ChAd63-KH vaccine for the prevention of post kala azar dermal leishmaniasis (PKDL). The ChAd63-KH vaccine will be evaluated in clinically cured visceral leishmaniasis patients aged 12-50 years in a safety and efficacy phase IIb clinical trial powered to detect a reduction in PKDL incidence. The results of this trial will be decisive in the future development of the ChAd63-KH vaccine
Additionally, to better understand the disease as well as drug and vaccine responses, multidimensional, multiparameter phenotyping will be conducted on patient cohorts recruited across the countries of the Leishmaniasis East Africa Platform (LEAP; Ethiopia, Kenya, Sudan and Uganda). A major aim of PREV_PKDL project is to support LEAP in its ambitions, by extending its research capacity in immunology and vaccine development. This will be achieved through a program to strengthen immunology research capacity through the development of a flow cytometry network across LEAP. This capacity strengthening will help LEAP to develop as a major force for research and training on poverty-related neglected diseases in the East African Region.
European Vaccine Initiative (EVI) (Germany); Institute of Endemic Diseases (IEND) (Sudan); Kenya Medical Research Institute (KEMRI) (Kenya); Makerere University (Uganda); University of Gondar (Ethiopia); University of York (UK).